Dániel Szűcs

Dániel Szűcs

Auto-generated profile, based on publicly available information

Dániel Szűcs

Department of Paediatrics and Paediatric Health Center, University of Szeged, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DSDániel Szűcs
Dániel Szűcs
NBNóra Judit Béres
Nóra Judit Béres
RRRéka Rokonay
Réka Rokonay
KBKriszta Boros
Kriszta Boros
KBKatalin Borka
Katalin Borka
GVGábor Veres
Gábor Veres
AIM: To evaluate the role of microRNA (miR)-146a, -155 and -122 in the duodenal mucosa of pediatric patients with Crohn’s disease (CD) and the effect of transforming growth factor-β (TGF-β) on these miRs in duodenal epithelial and fibroblast cells. METHODS: Formalin-fixed, paraffin-embedded biopsies derived from the macroscopically inflamed (CD inflamed: n = 10) and intact (CD intact: n = 10) duodenal mucosa of pediatric CD patients and control children (C: n = 10) were examined. Expression of miR-146a, -155 and -122 was determined by real-time polymerase-chain reaction (PCR). The expression of the above miRs was investigated in recombinant human TGF-β (1 nmol/L, 24 h) or vehicle treated small intestinal epithelial cells (CCL-241) and primary duodenal fibroblast cells derived from healthy children as well. RESULTS: Expression of miR-146a was significantly higher in the inflamed duodenal mucosa compared to the intact duodenal mucosa of children with CD (CD inflamed: 3.21 ± 0.50 vs CD intact: 0.62 ± 0.26, P≤ 0.01) and to the control group (CD inflamed: 3.21 ± 0.50 vs C: 1.00 ± 0.33, P≤ 0.05). The expression of miR-155 was significantly increased in the inflamed region of the duodenum compared to the control group (CD inflamed: 4.87 ± 1.02 vs Control: 1.00 ± 0.40, P≤ 0.001). The expression of miR-122 was unchanged in the inflamed or intact mucosa of CD patients compared to controls. TGF-β treatment significantly decreased the expression of miR-155 in small intestinal epithelial cells (TGF-β: 0.7 ± 0.083 vs Control: 1 ± 0.09, P≤ 0.05) and also the expression of miR-146a (TGF-β: 0.67 ± 0.04 vs Control: 1 ± 0.15, P≤ 0.01) and miR-155 (TGF-β: 0.72 ± 0.09 vs Control: 1 ± 0.06, P≤ 0.05) in primary duodenal fibroblasts compared to corresponding vehicle treated controls. TGF-β treatment did not influence the expression of miR-122. CONCLUSION: The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. Anti-inflammatory TGF-β plays an important role in the regulation of the expression of these miRs.

1 January 2021 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
BBBrigitta Balogh
Brigitta Balogh
DSDániel Szűcs
Dániel Szűcs
GGGabriella Gavallér
Gabriella Gavallér
ARAnna Rieth
Anna Rieth
TKTamás Kovács
Tamás Kovács
Balogh B, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 May;24(3):273-278. https://doi.org/10.5223/pghn.2021.24.3.273

10 November 2025 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
IKIlona Kiss
Ilona Kiss
ATAndrea Takacs
Andrea Takacs
SDSzűcs Dániel
Szűcs Dániel
MBMátyás Bukva
Mátyás Bukva
TPTímea Puskás
Tímea Puskás
IFImre Földesi
Imre Földesi
Objective: Differentiating between functional and organic gastrointestinal disorders in infants and young children remains a diagnostic challenge. Faecal calprotectin (FC) has emerged as a non-invasive biomarker that can help to exclude organic pathology. This study aimed to establish age-specific reference ranges for FC in healthy Hungarian children aged 0–36 months, providing a practical tool for paediatric clinical decision-making. Methods: A total of 282 stool samples were obtained from 245 healthy children (142 boys, 103 girls). Eligibility was determined using strict inclusion criteria based on parental interviews and questionnaires. FC concentrations were measured with a single-test ELISA assay (Orgentec Sebia Diagnostika). Data analysis employed Random Forest Regression and non-parametric statistical methods, following the Clinical and Laboratory Standards Institute EP28-A3c guideline. Results: Median FC concentrations by age group were: 0–4 months, 181 µg/g (IQR 92.5–289.6); 4–12 months, 40.6 µg/g (IQR 14.2–100.3); and 12–36 months, 24.7 µg/g (IQR 4.62–59.27). FC levels peaked in the youngest age group (0–4 months) and declined steadily thereafter, showing a consistent downward shift in both median and upper percentile values with increasing age. No significant associations were found between FC and gender, birth weight, mode of delivery or type of nutrition. Conclusions: This study provides age-specific reference values for FC in Hungarian children under 3 years of age. These results support the clinical use of FC testing to help exclude organic gastrointestinal disease, while emphasising the importance of appropriate test indication. The assay used proved to be reliable, minimally invasive, cost-effective and well suited for routine paediatric practice.